Anticancer drugs aimed at molecular regulators, including epidermal growth factor receptor (EGFR or HER1), its homologue c-erb-2 (HER2), have been developed and shown to be effective in the breast, lung, and colon cancers (Slamon et al, 2001; Thatcher et al, 2005; Gatzemeier et al, 2007; Sobrero et al, 2008). The gene discussed is EGFR; the disease is malignant colon neoplasm.